Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claes Held

Showing results (161-170 of 227) with videos related to

Pageof 23
Sort By:
American Heart Journal|January 2, 2022
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018Abhinav Sharma, Kenneth W Mahaffey, Charles Michael Gibson, et al.
European Heart Journal|December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialClaes Held, Elaine M Hylek, John H Alexander, et al.
The American Journal of Cardiology|January 22, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)Kenneth W Mahaffey, Zhen Huang, Lars Wallentin, et al.
Journal of the American College of Cardiology|January 4, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trialClaes Held, Nils Asenblad, Jean Pierre Bassand, et al.
Journal of the American College of Cardiology|October 18, 2020
Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic PlaqueGregg W Stone, Akiko Maehara, Ziad A Ali, et al.
Journal of the American College of Cardiology|May 7, 2016
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER TrialPascal Vranckx, Harvey D White, Zhen Huang, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 25, 2015
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxarJean-Pierre Déry, Kenneth W Mahaffey, Pierluigi Tricoci, et al.
American Heart Journal|March 21, 2016
Pooled analysis of adverse event collection from 4 acute coronary syndrome trialsAndré Zimerman, Renato D Lopes, Amanda L Stebbins, et al.
European Heart Journal|March 27, 2013
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trialSergio Leonardi, Pierluigi Tricoci, Harvey D White, et al.
Circulation. Cardiovascular Interventions|September 25, 2024
Impact of Lipidic Plaque on In-Stent and Stent Edge-Related Events After PCI in Myocardial Infarction: A PROSPECT II SubstudyLars Kjøller-Hansen, Akiko Maehara, Henning Kelbæk, et al.
Pageof 23

Showing results (161-170 of 227) with videos related to

Sort By:
Pageof 23
American Heart Journal|January 2, 2022
Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions - proceedings from the CEC Summit 2018Abhinav Sharma, Kenneth W Mahaffey, Charles Michael Gibson, et al.
European Heart Journal|December 16, 2014
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trialClaes Held, Elaine M Hylek, John H Alexander, et al.
The American Journal of Cardiology|January 22, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)Kenneth W Mahaffey, Zhen Huang, Lars Wallentin, et al.
Journal of the American College of Cardiology|January 4, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trialClaes Held, Nils Asenblad, Jean Pierre Bassand, et al.
Journal of the American College of Cardiology|October 18, 2020
Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic PlaqueGregg W Stone, Akiko Maehara, Ziad A Ali, et al.
Journal of the American College of Cardiology|May 7, 2016
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER TrialPascal Vranckx, Harvey D White, Zhen Huang, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 25, 2015
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxarJean-Pierre Déry, Kenneth W Mahaffey, Pierluigi Tricoci, et al.
American Heart Journal|March 21, 2016
Pooled analysis of adverse event collection from 4 acute coronary syndrome trialsAndré Zimerman, Renato D Lopes, Amanda L Stebbins, et al.
European Heart Journal|March 27, 2013
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trialSergio Leonardi, Pierluigi Tricoci, Harvey D White, et al.
Circulation. Cardiovascular Interventions|September 25, 2024
Impact of Lipidic Plaque on In-Stent and Stent Edge-Related Events After PCI in Myocardial Infarction: A PROSPECT II SubstudyLars Kjøller-Hansen, Akiko Maehara, Henning Kelbæk, et al.
Pageof 23